TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

Acta Biomedica Scientia

Volume 13, Issue 1, 2026
Mcmed International
Acta Biomedica Scientia
Issn
2348 - 215X (Print), 2348 - 2168 (Online)
Frequency
bi-annual
Email
editorabs@mcmed.us
Journal Home page
http://mcmed.us/journal/abs
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
LOW-DOSE PULSE CYCLOPHOSPHAMIDE THERAPY AS A TREATMENT FOR REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA: A PROSPECTIVE STUDY
Author
Dr. Saritha Suryadevara, Dr. Nagachakravarthy Mareedu
Email
keyword
Autoimmune hemolytic anemia, Low-dose pulse cyclophosphamide, Refractory AIHA, Partial remission, Treatment efficacy
Abstract
Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the destruction of red blood cells caused by autoantibodies. Managing severe, refractory AIHA is particularly challenging for patients who do not respond to steroids or other immunosuppressive treatments. This study investigates the effectiveness of low-dose pulse cyclophosphamide therapy (1g/month for four months) as an alternative to splenectomy and rituximab. A total of 34 patients (20 males and 14 females) aged 21 to 53 years were included in the study. Significant improvements were observed, with hemoglobin levels rising and reticulocyte counts decreasing after treatment. By the fourth cycle, 83% of patients achieved partial remission (PR), and 42% maintained hemoglobin levels ?10 g/dL without the need for transfusion. Six months after completing the treatment, complete remission (CR) was seen in several patients. No major adverse effects were noted during the study. These results suggest that low-dose pulse cyclophosphamide could be a promising, cost-effective treatment option for refractory AIHA, and further large-scale studies are recommended to validate these findings.
Download Broucher
Back to Top >>>>